Syndax Pharmaceuticals Inc Targeted Oncology Panel at Citi Biopharma Co-Panel Day (Virtual) Transcript
Okay. Great. Welcome, everyone, to the Targeted Oncology panel. My name is Yigal Nochomovitz. I'm one of the biotech analysts here at Citi. It's my pleasure to have with me 4 CEOs from important Targeted Oncology companies. From Ideaya, Yujiro Hata, who's the Co-Founder and CEO; from Oric, Jacob Chacko, President and CEO; and from Rain, Avanish Vellanki CEO; and finally, from Syndax, Michael Metzger, also CEO. So gentlemen, welcome all of you. Thank you very much for taking a bit of time out of your super busy schedules to chat.
So I think to start out to level set, if you wouldn't mind just for each of you running through very, very quickly 1, 2 minutes, just a very brief introduction to the company, the key pipeline levers. And then as well, please just mention the catalysts that are coming up for your pipeline in the next 6 to 18 months. That would be great. Maybe if you could just go down the list starting with Yujiro.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
